Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.32 |
| ▸ | CDK1 | P06493 | 2/20 | 0.31 |
| ▸ | CDK4 | P11802 | 2/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.31 |
| ▸ | CCND1 | P24385 | 2/20 | 0.31 |
| ▸ | CDK2 | P24941 | 2/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.30 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3471283 | 0.88 | KCNH2 (0.36) | ALDH1A1MAPTHPGDCDK1CDK4 | |
| SCHEMBL13638432 | 0.85 | IKBKB (0.39) | HPGDHDAC8 | |
| SCHEMBL13638473 | 0.84 | HDAC8 (0.34) | HDAC8CDK1CDK4CCNB1CCNA2 | |
| SCHEMBL13638534 | 0.82 | JAK2 (0.39) | HDAC8SYK | |
| SCHEMBL16192847 | 0.80 | KCNH2 (0.37) | CDK1CDK4CCNB1CCNA2CCND1 | |
| SCHEMBL13638664 | 0.79 | IKBKB (0.33) | HDAC8CDK4EIF2AK2 | |
| SCHEMBL3472852 | 0.79 | KCNH2 (0.36) | — | |
| SCHEMBL13638569 | 0.78 | AKT3 (0.37) | CDK1CDK4CCNB1CCNA2CCND1 | |
| SCHEMBL13638578 | 0.78 | IKBKB (0.37) | CDK1CDK4CCNB1CCNA2CCND1 | |
| SCHEMBL13638522 | 0.77 | IKBKB (0.36) | CDK1CDK4CCNB1CCNA2CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615562-B2 | Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents | NOVARTIS AG (CH) | 2009-11-10 | — | — | US | disclosed |
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | TPMT, IKBKB, CHUK | ALDH1A1 2035/4885MAPT 3501/4885HPGD 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.